囊性纤维化携带者状态与ERCP后胰腺炎风险的关联
单中心回顾性队列研究纳入3057例首次ERCP患者,其中249例为囊性纤维化携带者(CFC)。CFC组ERCP后胰腺炎(PEP)发生率显著高于非CFC组(17.7% vs 4.6%,P < .001),其他不良事件无差异。提示CFC状态可能增加PEP易感性,需优化术前风险评估与预防。
要点
- CFC患者首次ERCP后PEP发生率显著高于非CFC患者。
- CFC与非CFC患者的人口学特征及ERCP操作特征无显著差异。
- CFC状态或可纳入ERCP术前PEP风险评估。
核心结论
- 囊性纤维化携带者状态可能增加ERCP后胰腺炎的易感性。
研究设计与样本
- 单中心回顾性队列研究,纳入3057例首次ERCP患者,其中249例为囊性纤维化携带者。
主要发现
- CFC组PEP发生率为17.7%,非CFC组为4.6%,差异显著(P < .001)。
- 两组人口学特征及ERCP操作特征无显著差异,其他不良事件发生率无差异。
临床怎么用
- 对囊性纤维化携带者行ERCP前应加强PEP风险评估与预防措施。
局限性
- 单中心回顾性设计可能限制结论的外推性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Cystic fibrosis (CF) is recessive and due to CF transmembrane conductance regulator gene mutations. CF transmembrane conductance regulator mutation heterozygotes (CF carriers [CFCs]) are predisposed to CF-associated conditions, including pancreatitis. Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is a common adverse event after ERCP. Here we evaluate whether CFC status predisposes to PEP. METHODS: This single-center retrospective cohort study evaluated CFCs and presumed non-CFC patients undergoing index ERCP. We analyzed demographics, indications, interventions, and adverse events using descriptive statistics. RESULTS: Among 3057 patients, 249 were CFCs. No significant differences were found in demographics or ERCP characteristics between CFCs and non-CFCs. However, the rate of PEP was significantly higher in CFCs (17.7% vs 4.6%, P < .001), whereas other adverse events did not differ. CONCLUSIONS: CFC status appears to increase predisposition to PEP, highlighting the potential for improved preprocedural risk assessment and prophylaxis and opportunities for further study to identify novel PEP prophylactic strategies.
引用
- Barakat MT, Akhtar D, Yasui OW, et al. Cystic fibrosis carrier status: a genetic predisposition to post-endoscopic retrograde cholangiopancreatography pancreatitis. Gastrointest Endosc. 2025. PMID: 41083013. doi:10.1016/j.gie.2025.10.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。